1. Home
  2. DVAX vs EVH Comparison

DVAX vs EVH Comparison

Compare DVAX & EVH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVAX
  • EVH
  • Stock Information
  • Founded
  • DVAX 1996
  • EVH 2011
  • Country
  • DVAX United States
  • EVH United States
  • Employees
  • DVAX N/A
  • EVH N/A
  • Industry
  • DVAX Biotechnology: Pharmaceutical Preparations
  • EVH Other Consumer Services
  • Sector
  • DVAX Health Care
  • EVH Consumer Discretionary
  • Exchange
  • DVAX Nasdaq
  • EVH Nasdaq
  • Market Cap
  • DVAX 1.2B
  • EVH 1.0B
  • IPO Year
  • DVAX 2004
  • EVH 2015
  • Fundamental
  • Price
  • DVAX $10.15
  • EVH $8.14
  • Analyst Decision
  • DVAX Buy
  • EVH Strong Buy
  • Analyst Count
  • DVAX 4
  • EVH 15
  • Target Price
  • DVAX $26.50
  • EVH $17.07
  • AVG Volume (30 Days)
  • DVAX 1.7M
  • EVH 3.1M
  • Earning Date
  • DVAX 11-06-2025
  • EVH 11-06-2025
  • Dividend Yield
  • DVAX N/A
  • EVH N/A
  • EPS Growth
  • DVAX N/A
  • EVH N/A
  • EPS
  • DVAX N/A
  • EVH N/A
  • Revenue
  • DVAX $316,268,000.00
  • EVH $2,195,920,000.00
  • Revenue This Year
  • DVAX $23.23
  • EVH N/A
  • Revenue Next Year
  • DVAX $16.57
  • EVH $28.32
  • P/E Ratio
  • DVAX N/A
  • EVH N/A
  • Revenue Growth
  • DVAX 26.66
  • EVH N/A
  • 52 Week Low
  • DVAX $9.20
  • EVH $7.06
  • 52 Week High
  • DVAX $14.63
  • EVH $27.42
  • Technical
  • Relative Strength Index (RSI)
  • DVAX 52.11
  • EVH 39.72
  • Support Level
  • DVAX $9.95
  • EVH $7.84
  • Resistance Level
  • DVAX $10.35
  • EVH $9.63
  • Average True Range (ATR)
  • DVAX 0.29
  • EVH 0.47
  • MACD
  • DVAX 0.08
  • EVH -0.05
  • Stochastic Oscillator
  • DVAX 75.00
  • EVH 10.03

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About EVH Evolent Health Inc

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

Share on Social Networks: